Skip to ContentSkip to Navigation
breed in kennis  -  sterk in techniek
Over ons Praktische zaken Waar vindt u ons dr. M. Nijland

Publicaties

Development of an LC-MS/MS Method for Simultaneous Quantification of Ibrutinib and Ritonavir in Plasma and Dried Plasma Spots

Dynamics of circulating tumour DNA in relapsed/refractory diffuse large B-cell lymphoma patients

Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial

Ibrutinib tablet splitting as a practical strategy for dose reduction in the management of drug–drug interactions

Immunodeficiency-associated primary CNS lymphomas: an International Primary CNS Lymphoma Collaborative Group study

Impact of Rituximab Maintenance on Survival in Patients with Mantle Cell Lymphoma; a Population-based Cohort Study

Moving beyond R-CHOP in large B-cell lymphoma

Prospective Validation of Circulating Tumor DNA Measurable Residual Disease After First-Line Therapy in Large B-Cell Lymphoma

Real-World Outcomes of High Dose Melphalan and Autologous Stem Cell Transplantation in Patients With Multiple Myeloma Older and Younger Than 65 Years

Safety and efficacy of currently used drug therapies for treatment of lymphomas in patients with Sjögren's disease, a scoping review

Pers/media

La consolidation de l’atezolizumab impressionne dans le DLBCL à haut risque

Atezolizumab Consolidation Impresses in High-Risk DLBCL

Rituximab Biosimilars Versus Originator: Comparing Long-Term Survival Benefit in DLBCL

Medtalks:Diffuus Grootcellig B-cellymfoom 2018

Sustainable Development Goals

SDG 3 – Goede gezondheid en welzijnSDG 9 – Industrie, innovatie en infrastructuur

Meer informatie over de Sustainable Development Goals.